INM-755 is a cannabinol topical cream under development for the treatment of epidermolysis bullosa. INM-755 for EB is the first cannabinol formulation to reach clinical trials as a therapeutic product.

INM-088 is a topical eye drop formulation under development for the treatment of glaucoma. The active pharmaceutical ingredient (API) in INM-088 is cannabinol, also known as CBN, a rare cannabinoid showing promise in its potential to provide neuroprotection and to reduce intraocular pressure of the eye.

InMed is researching and developing rare cannabinoids as potential therapeutics for unmet medical needs. While the most prevalent cannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD), are being widely used for a variety of reasons, evidence suggests there may be greater therapeutic potential in rare cannabinoids that are found in very small traces in the cannabis plant. Cannabinol, a rare cannabinoid, is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

In parallel to InMed’s therapeutic development programs, InMed is developing a cannabinoid synthesis manufacturing system to produce cost-effective, pharmaceutical-grade, bio-identical cannabinoids. Plant extraction is not feasible to meet long-term pharmaceutical demand of cannabinoid therapeutics, particularly rare cannabinoids.